Argenica Therapeutics Ltd (agn) Logo

Argenica Therapeutics Ltd (AGN)

___:___ · AUD
0.00
0.00
(0.00)
VOLUME
DIV YIELD
PE RATIO
1 YR RETURN
52 WEEK RANGE

AGN Chart

AGN's Principal Activity is the development and commercialisation of a novel therapeutic.

Share Price Activity

Last (Price)
Change 0.00 (0.00)
Bid / Ask -
Volume
Volume (4w avg)
Turnover
Open
Day Range -
VWAP
Prev Close
Last Trade

Performance

1 Week
1 Month
2021 YTD
1 Year
vs Sector (1yr) -
vs ASX 200 (1yr) -19.67%

Size

Market Capitalisation
ASX Rank 2,017 of 2,295
Sector Rank

Key Information

Shares Issued
Sector Healthcare
Similar Companies -
EPS $0.00
DPS $0.00
NTA per share $0.00

Broker Consensus

AGN is not covered by a major broker, or data from most recent compilation was omitted due to not meeting QA guidelines.

Announcements

Date Heading Pages File Size Time

Company Overview

Argenica Therapeutics Limited (AGN) operated in development and commercialisation of a novel drug developed by world-leading researchers at the University of Western Australia (UWA) and the Perron Institute for Neurological and Translational Science (Perron Institute). Argenica's current business is to develop a best in class neuroprotective drug based on the pioneering work of Assoc.

Incorporation Details

No incorporation details available.

Corporate Details

Head Office Nedlands WA 6009
Website www.argenica.com.au
Registry Link Market Services
Auditor RSM Australia Partners
Date Listed 11 Jun 2021

Upcoming Calendar (Forecasted)

No calendar entries available.

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date Amount Franking Gross Type Payable
No dividends paid.

See Upcoming Dividends for all ASX companies.

Directors & Management

Directors & Management

Name Title Since Bio
Mr Terrence (Terry) Charles Budge Non-Executive Director Jan 2021 Director Bio icon

Mr Terrence (Terry) Charles Budge

Non-Executive Director

Mr Budge was a Director of Aspen Group Limited from 6 May 2005 to 23 November 2012. He was also Chancellor of Murdoch University from 2006 to 2013 (appointed to Senate 1 June 2004). He is currently a non-executive director and Chairman of the Audit Committee of Westoz Investment Company Ltd (ASX:WIC). He is also the Chairman of the Risk Management Committee of the AGN.

Ms Elizabeth (Liddy) McCall Non-Executive Director Dec 2020 Director Bio icon

Ms Elizabeth (Liddy) McCall

Non-Executive Director

Ms McCall has co-founded early state venture fund, Yuuwa Capital LP and has over 20 years' experience as a founder, investor and in management of early-stage startups. Her prior experience includes co-founder of iCeutica Inc group, Dimerix Limited (ASX: DXB) and Argus Biomedical Pty Ltd. Previously, Ms McCall was an Associate Director, Macquarie Bank focusing on mergers and acquisitions. Ms McCall is on the Board of various companies including ASX listed AdAlta Limited (ASX:1AD), and unlisted companies, Agworld Pty Ltd, Nexgen Plants Pty Ltd, The Tailor Made Spirits Company Limited and Super Trans Medical Limited. She is also member of the Risk Management Committee of the AGN.

Dr Samantha (Sam) South Executive Director Mar 2020 Director Bio icon

Dr Samantha (Sam) South

Executive Director

Dr South is currently the Senior Commercialisation Officer (Life Sciences) in the Research Development & Innovation office at UWA and has over 12 years' experience in technology transfer in medtech / biotech sector, at the University of Queensland (UQ), Queensland University of Technology and the University of Western Australia (UWA). Dr South has background in medical research at Weill Medical College at Cornell University (NY), UQ and The Garvan Institute in CNS research. She was also the Preclinical Manager at TetraQ, a preclinical contract organisation, specializing in central nervous system animal models. Dr South was the UWA Director on UWA spin-out companies, MiReven Pty Ltd, Eridan Technologies Pty Ltd and OncoRes Medical Pty Ltd and is currently a Director of Rage Biotech Pty Ltd. Dr South is also the WA Ausbiotech Committee Chair and part of the Ausmedtech National Advisory Group and SBE Life Sciences Council.

Mr Geoffrey (Geoff) Richard Pocock Non-Executive Chairman,Non-Executive Director Nov 2019 Director Bio icon

Mr Geoffrey (Geoff) Richard Pocock

Non-Executive Chairman,Non-Executive Director

Mr Pocock has over 20 years' experience across the commercialisation process. Mr Pocock's experience has covered technical roles, executive management as well as corporate finance and strategy roles with a number of technology commercialisation ventures. Mr Pocock is the Principal of Polaris Consulting, a specialist boutique commercialisation strategy and executive services advisory business based in Western Australia, which also provides administrative services to businesses. He is also currently an Executive Director of Osteopore Ltd (ASX:OSX) and NonExecutive Director of EMVision Medical Devices Ltd (ASX:EMV) and former Managing Director/Co-Founder of Hazer Group (ASX: HZR). He is also member of the Risk Management Committee of the AGN.

Ms Emma Waldon Chief Financial Officer,Company Secretary N/A
Dr Liz Dallimore Chief Executive Officer N/A
Liz Dallimore Chief Executive Officer N/A

Director Interests

The current holdings of AGN directors.

Director Last Notice Direct Shares Indirect Shares Options Convertibles
Terrence (Terry) Budge 21/01/2021 N/A 455,000 500,000 N/A
Elizabeth (Liddy) McCall 16/12/2020 N/A 125,000 500,000 N/A
Samantha (Sam) South 24/03/2020 N/A 2,000,000 1,000,000 N/A
Geoffrey (Geoff) Pocock 20/11/2019 N/A 4,377,000 500,000 N/A

Shareholder Info

Top 20 Shareholders About the Data

Data supplied by Morningstar and accurate on Jun 3, 2021.

It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.

All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).

Name Shares Capital
Oofy Prosser Pty Ltd (Drones Family A/C) 4,377,000 5.98%
University Of Western Australia 3,953,000 5.40%
Perron Institute For Neurological And Translational Science Ltd 3,550,000 4.85%
Shane Michael Colley (Fiery King Investment A/C) 2,000,000 2.73%
Shane Hoehock Wee (Wee Family A/C) 1,794,250 2.45%
Altor Capital Management Pty Ltd (Altor Alpha Fund A/C) (i) 1,750,000 2.39%
Arredo Pty Ltd 1,550,000 2.12%
Litis Super Pty Ltd (Jde Litis Super Fund A/C) 1,500,000 2.05%
Helen Margaret Sewell 1,472,500 2.01%
Xcel Capital Pty Ltd 1,462,500 2.00%
Bruno Philip Meloni (Bruno Meloni Family A/C) 1,277,000 1.75%
Ga Skylight Berhad 1,250,000 1.71%
Mr Neville William Knuckey & Mrs Jacqueline Joy Knuckey 1,072,000 1.47%
Busso Holdings Pty Ltd (Bew) 1,025,000 1.40%
Asenna Wealth Solutions Pty Ltd 900,000 1.23%
Altor Capital Management Pty Ltd (Altor Alpha Fund A/C) (ii) 872,500 1.19%
Pentek Holdings Pty Ltd (The J Litis Investment No.2 A/C) 785,000 1.07%
Hugh James Pilgrim (The HJP Family A/C) 734,500 1.00%
Morsec Nominees Pty Ltd (Accumulation Account) 690,000 0.94%
Kdjama Co Pty Ltd (Blacker Services A/C) 655,750 0.90%

Shareholder Distribution

As reported in the most recent Annual Report.

Holding Size 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001+ Total
No. of Shareholders 0 0 56 462 121 639

Substantial Shareholders

No Substantial Shareholders for AGN in our database.

Shareholders Buying

12 month transaction history compiled from ASX announcements.

No buy transactions reported by Substantial Shareholders in the past 12 months.

Shareholders Selling

12 month transaction history compiled from ASX announcements.

No sell transactions reported by Substantial Shareholders in the past 12 months.

Historical Data

Share Price History

Date Close Change %Chg Open High Low Volume Turnover

Historical Data

Year Closing Price Last Trade
No Financial Year End data available
Page Icon
AGN Historical Price Data (CSV)
Up to 20 years of EOD share price history
Lock Icon
You must be logged in to access this feature. Please sign up for free or login.
Market Index, ASX and Morningstar Logos

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.